{"links":{"feed":"https://www.erudio.com/reports/gimema-all2820-nct04722848/feed.json","html":"https://www.erudio.com/reports/gimema-all2820-nct04722848","json":"https://www.erudio.com/reports/gimema-all2820-nct04722848.json","markdown":"https://www.erudio.com/reports/gimema-all2820-nct04722848.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"gimema-all2820-nct04722848"}},"request":"https://www.erudio.com/contact?report=gimema-all2820-nct04722848"},"offer":{"cited_clinicians":15,"cited_commentary_sources":68,"verified_hcp_statements":480,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":24},"for_sale":true,"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"gimema-all2820-nct04722848"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=gimema-all2820-nct04722848","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/gimema-all2820-nct04722848","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_line":"Deep · 480 verified statements · 85 from 15 confirmed clinicians","size_rule":"Deep: 301+ verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T18:36:39.581269Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":25,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":10,"title":"Primary endpoint: Number of patients who are event-free"},{"claim_count":23,"coverage":"discussed","id":"T2","registry_field":"conditionsModule","source_count":14,"title":"Population and setting"},{"claim_count":44,"coverage":"discussed","id":"T3","registry_field":"armsInterventionsModule.armGroups","source_count":18,"title":"The comparison"},{"claim_count":42,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.interventions","source_count":21,"title":"Safety and tolerability"},{"claim_count":42,"coverage":"discussed","id":"T5","registry_field":"designModule","source_count":14,"title":"Design and conduct"},{"claim_count":55,"coverage":"discussed","id":"A1","source_count":22,"title":"Transplant selection, omission and high-risk exceptions"},{"claim_count":22,"coverage":"discussed","id":"A2","source_count":14,"title":"MRD definitions, assay discordance and longitudinal interpretation"},{"claim_count":42,"coverage":"discussed","id":"A3","source_count":18,"title":"OS, rescue crossover and differences between presentation and publication accounts"},{"claim_count":33,"coverage":"discussed","id":"A4","source_count":16,"title":"CNS relapse prevention and the limits of transferring external risk thresholds"},{"claim_count":40,"coverage":"discussed","id":"A5","source_count":16,"title":"Treatment sequencing, dose adaptation, maintenance and infusion support"},{"claim_count":21,"coverage":"discussed","id":"A6","source_count":8,"title":"Drug access, authorization, affordability and economic trade-offs"},{"claim_count":12,"coverage":"discussed","id":"A7","source_count":5,"title":"Quality of life, function and patient expectations"},{"claim_count":8,"coverage":"discussed","id":"A8","source_count":3,"title":"Laboratory networks, independent research and translation into broad access"},{"claim_count":41,"coverage":"discussed","id":"A9","source_count":34,"title":"Perceived practice change versus confirmation of an existing preference"},{"claim_count":5,"coverage":"discussed","id":"A10","source_count":4,"title":"Further immunotherapy and possible CAR-T consequences beyond the tested arms"}],"counts":{"cited_clinicians":15,"cited_clinicians_by_role":{"physician":5,"physician, Hematology and oncology":4,"physician, Internal medicine":1,"physician, Medical oncology":5},"cited_physicians":15,"cited_sources":69,"claims_by_expression_type":{"comparison":48,"experience":7,"interpretation":156,"opinion":102,"primary_context":13,"question":11,"restatement":60,"uncertainty":38,"unspecified":45},"claims_by_kind":{"interpretation":3,"objective_result":1,"protocol_statement":1,"publication_statement":1,"source_observation":474},"clinician_statements":85,"evidence_units":239,"findings":11,"organisational_accounts":6,"people_cited":35,"people_identity_verified":24,"people_total":35,"screened_sources":108,"verified_claims":480},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":75,"claims_by_group":{"comparisons":6,"experience":1,"questions":4,"restated":12,"views":52},"limitations":2,"links":{"context":4,"support":82},"ma_question":true,"named_voices":14,"passages":63,"sources":26,"sources_by_kind":{"commentary":13,"media":13}},"title":"CR1 HCT: what speakers say","evidence_line":"75 statements from 14 speakers in 26 sources, 13 of them podcasts or videos"},{"cited_clinicians":7,"id":"F2","structure":{"claims":55,"claims_by_group":{"comparisons":5,"experience":0,"questions":4,"restated":10,"views":36},"limitations":2,"links":{"context":9,"support":63},"ma_question":true,"named_voices":13,"passages":51,"sources":24,"sources_by_kind":{"commentary":14,"media":10}},"title":"TKIs: most speakers flag ponatinib's vascular risk; some consider dasatinib","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-7e73f97980d8b0d1e40f","claim-c5e3c59d310b6701c2e0","claim-dfd7c11a320e79601eed","claim-9bf7c30541b5a02b10c0","claim-0b5cc89520afffe1f487","claim-41bbeb41d5cec679dc66","claim-e26ff19bf7eb8cf9a0c8","claim-5ffb0aeb117093577790","claim-011d9df70b7ef4d421a0"],"clause":"some consider dasatinib","holders":3},"cited_claim_ids":["claim-ed8cd4747ac0fb84d64f","claim-f497830457b5d70efa72","claim-ef9b098acab5a7402773","claim-8c2da1002b7ef475e079","claim-7e73f97980d8b0d1e40f","claim-e406a11a67cacb426f34","claim-d0db6a0e9fce9beb7cb9","claim-dfd7c11a320e79601eed","claim-a41f7bbd5c0c42cbadbc","claim-decd6bec1cb3c5503cc6","claim-0b5cc89520afffe1f487","claim-7e7a8458a6a12adf8792","claim-02d1e84029dfd4d81239","claim-37e407cc0b0c2dcebda8","claim-05fa54c24ea997ad3e04","claim-913e0ea6104036dbb38d","claim-a2224bdd0f8414ede6e9","claim-f9aa19c43f468e8d97db","claim-6042a9fba38f567e4b40","claim-a58cf2435d56a78f6cc5","claim-66cb74949bfd3fb1582c","claim-3cd4e1095ffbb298ce15","claim-58b5afc2378a2a7d073e","claim-e26ff19bf7eb8cf9a0c8","claim-1eee088673aec9e222a2","claim-5d5df7cadeb0a4867f02","claim-5ffb0aeb117093577790"],"clinicians":false,"holders":8,"speakers":13,"view":"reading"},"evidence_line":"55 statements from 13 speakers in 24 sources, 10 of them podcasts or videos","holder_line":"8 of the 13 named speakers in this finding hold this view; 3 of the 13 hold its caveat, “some consider dasatinib”"},{"cited_clinicians":11,"id":"F3","structure":{"claims":131,"claims_by_group":{"comparisons":12,"experience":0,"questions":2,"restated":33,"views":84},"limitations":2,"links":{"context":9,"support":143},"ma_question":true,"named_voices":28,"passages":102,"sources":55,"sources_by_kind":{"commentary":36,"media":19}},"title":"Chemo-sparing Ph+ ALL: where speakers split on changing versus confirming practice","title_holders":{"cited_claim_ids":["claim-33687bd2dc9746411355","claim-a9d551f48290901e3a23","claim-db8492835d9a3d6895ec","claim-c8b76004cc2dcaa34f46","claim-0d602c692c93c8fa7b13","claim-05328a5ed57bf5604816","claim-9edca2b2f6c74e017e48","claim-9d0d9ee11721c93bb2fe","claim-6e334b498f93358a8a91","claim-2286fd12d368a54c8300","claim-f7972db0ff1c79defa61","claim-7604efec214210fd2c7a","claim-459013a0533111ebbeaf","claim-4d3125b0fcf5761dc566","claim-ce7f85e019b9440cd16f","claim-17ac3f8fcd9d4bcf4fe8","claim-306b60f932110d2e09bc","claim-c415ef1c37fb2a2c71d1","claim-58fceca56cf141f475fd","claim-48e6bf82495d3ab23a85","claim-742b81d3c5f0d027b38e","claim-11fb609269539125aa37","claim-ea1288c5f604f52e312c","claim-b3451f7972ad5a49e76c","claim-12ab6340c7a5350af71d","claim-b3451f7972ad5a49e76c-49285098","claim-4847e0550446c427cc17","claim-514c15634ce12d023e99","claim-cd0b97b44fbf2f5ced13","claim-c8b7068570b6d5b0f565","claim-2b79519d6d1bb5733f88","claim-da7c008b63bd380fb951","claim-52a55c9bf9b5029f6b65","claim-4f223c19df938651be9f","claim-b03a4395de3f9f1887a4","claim-7fbe29c9b1282254b2c6","claim-7f6d5177d61909973794","claim-c138a1857523887401e9","claim-3ce924e6a0c18881b2a3","claim-9c61e083f9e6d6210613","claim-a09b1e63f226b671ec40"],"clinicians":false,"holders":19,"sides":[{"cited_claim_ids":["claim-33687bd2dc9746411355","claim-a9d551f48290901e3a23","claim-db8492835d9a3d6895ec","claim-c8b76004cc2dcaa34f46","claim-0d602c692c93c8fa7b13","claim-05328a5ed57bf5604816","claim-9edca2b2f6c74e017e48","claim-9d0d9ee11721c93bb2fe","claim-6e334b498f93358a8a91","claim-2286fd12d368a54c8300","claim-f7972db0ff1c79defa61","claim-7604efec214210fd2c7a","claim-459013a0533111ebbeaf","claim-4d3125b0fcf5761dc566","claim-ce7f85e019b9440cd16f","claim-17ac3f8fcd9d4bcf4fe8","claim-306b60f932110d2e09bc","claim-c415ef1c37fb2a2c71d1","claim-58fceca56cf141f475fd","claim-48e6bf82495d3ab23a85","claim-742b81d3c5f0d027b38e","claim-11fb609269539125aa37","claim-ea1288c5f604f52e312c","claim-b3451f7972ad5a49e76c","claim-12ab6340c7a5350af71d","claim-b3451f7972ad5a49e76c-49285098","claim-4847e0550446c427cc17","claim-514c15634ce12d023e99","claim-cd0b97b44fbf2f5ced13","claim-c8b7068570b6d5b0f565","claim-2b79519d6d1bb5733f88","claim-da7c008b63bd380fb951","claim-52a55c9bf9b5029f6b65","claim-4f223c19df938651be9f","claim-b03a4395de3f9f1887a4","claim-7fbe29c9b1282254b2c6","claim-7f6d5177d61909973794"],"holders":16},{"cited_claim_ids":["claim-c138a1857523887401e9","claim-3ce924e6a0c18881b2a3","claim-9c61e083f9e6d6210613","claim-a09b1e63f226b671ec40"],"holders":4}],"speakers":28,"view":"split"},"evidence_line":"131 statements from 28 speakers in 55 sources, 19 of them podcasts or videos","holder_line":"19 of the 28 named speakers in this finding take a side on this question: 16 on one side, 4 on the other, 1 on both"},{"cited_clinicians":4,"id":"F4","structure":{"claims":53,"claims_by_group":{"comparisons":2,"experience":1,"questions":10,"restated":12,"views":28},"limitations":2,"links":{"context":1,"support":59},"ma_question":true,"named_voices":11,"passages":44,"sources":20,"sources_by_kind":{"commentary":10,"media":10}},"title":"OS readings: where speakers split on benefit amid crossover and short follow-up","title_holders":{"cited_claim_ids":["claim-0bf6929755188454baee","claim-45e80f189069c3d97047","claim-9d0d9ee11721c93bb2fe","claim-81a14d97c8e1e5b3f8c8","claim-19124014620ec801b751","claim-099a732cf87a4fed2ee4","claim-8cebc703336c4a62f312","claim-f7972db0ff1c79defa61","claim-00d0c01e783d2f869011","claim-0d74b05541c7cc3ecc24","claim-af193146b79ce3dcc604","claim-4115a30642659b1777d9","claim-cd71f6e6255da62fe8a9","claim-d94677fedd06969a50ee","claim-6c9fc89a4ee0f3e87a4c","claim-43cab5a85b11e6aea594","claim-be6bfd4649dfba41b8dc","claim-9986dd9a88fa891cc401","claim-d4e6fc91e25c4ddb1b35","claim-ab1846a64301fbdac4d1","claim-75e6e04a5e15ced37f61","claim-03202870190d6ab7c361","claim-9aead6bdeeb008cbec3c","claim-95ac417e6cdd6e3433d6","claim-085383b0c68f5ed7ad53","claim-202c9687a22bf73289c7","claim-617f0a7f4444cdb24bd9","claim-7882eb2be2a140096a60"],"clinicians":false,"holders":10,"sides":[{"cited_claim_ids":["claim-0bf6929755188454baee","claim-45e80f189069c3d97047","claim-9d0d9ee11721c93bb2fe","claim-81a14d97c8e1e5b3f8c8","claim-19124014620ec801b751","claim-099a732cf87a4fed2ee4","claim-8cebc703336c4a62f312","claim-f7972db0ff1c79defa61","claim-00d0c01e783d2f869011","claim-0d74b05541c7cc3ecc24","claim-af193146b79ce3dcc604","claim-4115a30642659b1777d9","claim-cd71f6e6255da62fe8a9","claim-d94677fedd06969a50ee","claim-6c9fc89a4ee0f3e87a4c","claim-43cab5a85b11e6aea594","claim-be6bfd4649dfba41b8dc","claim-9986dd9a88fa891cc401","claim-d4e6fc91e25c4ddb1b35","claim-ab1846a64301fbdac4d1","claim-75e6e04a5e15ced37f61","claim-03202870190d6ab7c361","claim-9aead6bdeeb008cbec3c","claim-95ac417e6cdd6e3433d6","claim-085383b0c68f5ed7ad53"],"holders":9},{"cited_claim_ids":["claim-202c9687a22bf73289c7","claim-0d74b05541c7cc3ecc24","claim-617f0a7f4444cdb24bd9","claim-7882eb2be2a140096a60"],"holders":2}],"speakers":11,"view":"split"},"evidence_line":"53 statements from 11 speakers in 20 sources, 10 of them podcasts or videos","holder_line":"10 of the 11 named speakers in this finding take a side on this question: 9 on one side, 2 on the other, 1 on both"},{"cited_clinicians":5,"id":"F5","structure":{"claims":72,"claims_by_group":{"comparisons":14,"experience":0,"questions":12,"restated":18,"views":28},"limitations":2,"links":{"context":4,"support":81},"ma_question":true,"named_voices":11,"passages":50,"sources":19,"sources_by_kind":{"commentary":10,"media":9}},"title":"Randomized ALL2820: where speakers split on the imatinib comparison's value today","title_holders":{"cited_claim_ids":["claim-2f5e439f565a0517dfe2","claim-80411ba6389daf1f8c16","claim-ff6225d84ab970bb552a","claim-e0ce22499922f8cefda9","claim-b20e9c25eee98208494c","claim-e26ff19bf7eb8cf9a0c8","claim-9b1159fa8ba00aa61802","claim-ab1846a64301fbdac4d1","claim-f9024d34fe19d1954ef8","claim-1868749867133a129a20","claim-bf2af8ffc6b4297e63ed","claim-570ff6ad5841d2ac9710","claim-63000b4eb692fc086c49","claim-fcbba4273ddcd2bbb308","claim-805999b7fa8f12e3aef8","claim-9f09cd5940162cf8f84b","claim-96ed4981e466099b3a0a","claim-2d793a8ac78e1133161e","claim-b737068f632281aed6a5","claim-234d6220746e8c20c227","claim-115668b43afa12631cdd","claim-3ddc271d199412cab29f","claim-a73dc614d33c313d8b42","claim-a068fc93a219cee4e8b7","claim-77e179fa0a22d1737ae1","claim-0f563234d27d7880802e","claim-011d9df70b7ef4d421a0"],"clinicians":false,"holders":10,"sides":[{"cited_claim_ids":["claim-2f5e439f565a0517dfe2","claim-80411ba6389daf1f8c16","claim-ff6225d84ab970bb552a","claim-e0ce22499922f8cefda9","claim-b20e9c25eee98208494c","claim-e26ff19bf7eb8cf9a0c8","claim-9b1159fa8ba00aa61802","claim-ab1846a64301fbdac4d1"],"holders":3},{"cited_claim_ids":["claim-f9024d34fe19d1954ef8","claim-1868749867133a129a20","claim-bf2af8ffc6b4297e63ed","claim-80411ba6389daf1f8c16","claim-570ff6ad5841d2ac9710","claim-63000b4eb692fc086c49","claim-fcbba4273ddcd2bbb308","claim-805999b7fa8f12e3aef8","claim-9f09cd5940162cf8f84b","claim-b20e9c25eee98208494c","claim-96ed4981e466099b3a0a","claim-2d793a8ac78e1133161e","claim-b737068f632281aed6a5","claim-234d6220746e8c20c227","claim-115668b43afa12631cdd","claim-3ddc271d199412cab29f","claim-a73dc614d33c313d8b42","claim-a068fc93a219cee4e8b7","claim-e26ff19bf7eb8cf9a0c8","claim-9b1159fa8ba00aa61802","claim-77e179fa0a22d1737ae1","claim-0f563234d27d7880802e","claim-011d9df70b7ef4d421a0"],"holders":8}],"speakers":11,"view":"split"},"evidence_line":"72 statements from 11 speakers in 19 sources, 9 of them podcasts or videos","holder_line":"10 of the 11 named speakers in this finding take a side on this question: 3 on one side, 8 on the other, 1 on both"},{"cited_clinicians":3,"id":"F6","structure":{"claims":22,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":3,"views":14},"limitations":2,"links":{"context":2,"support":22},"ma_question":true,"named_voices":7,"passages":21,"sources":14,"sources_by_kind":{"commentary":7,"media":7}},"title":"MRD-guided transplantation: why most speakers ask what a negative result means","title_holders":{"cited_claim_ids":["claim-898b89b33051d4f3d585","claim-592030e269cc753a7a50","claim-6ca43860f0a38cf20d3f","claim-b0cd135699c626353659","claim-09bb9664e72fd3d9c9f6","claim-17ac3f8fcd9d4bcf4fe8","claim-a29217a5bf6793d7993f","claim-dee5285cf97ec81d4351","claim-99fdd682706643676892","claim-4db87b8283332eead7e3","claim-7f5424ea64cf5223f588","claim-3737e7aae298e7b18328","claim-0699c047d8192622b33e","claim-4a5434b132db9b439d58","claim-4451f211bc0534a24204"],"clinicians":false,"holders":5,"speakers":7,"view":"reading"},"evidence_line":"22 statements from 7 speakers in 14 sources, 7 of them podcasts or videos","holder_line":"5 of the 7 named speakers in this finding hold this view"},{"cited_clinicians":2,"id":"F7","structure":{"claims":33,"claims_by_group":{"comparisons":5,"experience":1,"questions":6,"restated":6,"views":15},"limitations":2,"links":{"context":4,"support":35},"ma_question":true,"named_voices":7,"passages":33,"sources":16,"sources_by_kind":{"commentary":7,"media":9}},"title":"CNS prophylaxis: speakers stress it; a clinician cautions on relapse causality","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-319c50b528dcba6d56a2","claim-310903a59e4cf3e21769"],"clause":"a clinician cautions on relapse causality","holders":1},"cited_claim_ids":["claim-5766521775e3c34da416","claim-661ac84af8fc43165173","claim-319c50b528dcba6d56a2","claim-fb4d2d2c43a82e131696","claim-f5f01c26ae0c7c9ff8a6","claim-416bef78c3d354996cc8","claim-e5fa2380809f801306de","claim-310903a59e4cf3e21769","claim-91e0c1946f20ae7d7f64","claim-e716ecb5a86f4b330d53","claim-04bed788d88b5077c4d0","claim-d9b16747cd14ba556907","claim-c3eb856860cd1bff688f","claim-66cb74949bfd3fb1582c","claim-10441561d1dff6c86506","claim-8d8ca93154726a6a08ef","claim-fe3a764e4868879d5f1c","claim-60d07e887ba24dcd98b0"],"clinicians":false,"holders":7,"speakers":7,"view":"reading"},"evidence_line":"33 statements from 7 speakers in 16 sources, 9 of them podcasts or videos","holder_line":"7 of the 7 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician cautions on relapse causality”"},{"cited_clinicians":2,"id":"F8","structure":{"claims":29,"claims_by_group":{"comparisons":5,"experience":2,"questions":4,"restated":5,"views":13},"limitations":2,"links":{"context":6,"support":30},"ma_question":true,"named_voices":10,"passages":16,"sources":11,"sources_by_kind":{"commentary":5,"media":6}},"title":"Access and cost: most speakers see adoption barriers, but some weigh offsets","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-68266bdfc198ff134fa5","claim-a700bacb242411bcfa6c","claim-4fe1bece03a6795b6643"],"clause":"some weigh offsets","holders":3},"cited_claim_ids":["claim-5e1072092953fd7ccd05","claim-b13c6b2f3755fdf0ea9b","claim-bcd3d0fb94eb96924ded","claim-68266bdfc198ff134fa5","claim-1eeec44f454248262a98","claim-5a13f43eafb23d9509a2","claim-84d0e12d73c3d03190b8","claim-18b1dde9a14caa3365e7","claim-9c61e083f9e6d6210613","claim-bb7e5730914edf6e7b35","claim-0fb6a9683d12c1509e94","claim-caeafc7fc114044e28a7","claim-4fe1bece03a6795b6643","claim-97bc8cf7f1943179a062","claim-09387c3bcd93df6128c0","claim-84c368dbc0a0aec545f1"],"clinicians":false,"holders":7,"speakers":10,"view":"reading"},"evidence_line":"29 statements from 10 speakers in 11 sources, 6 of them podcasts or videos","holder_line":"7 of the 10 named speakers in this finding hold this view; 3 of them hold its caveat, “some weigh offsets”"},{"cited_clinicians":4,"id":"F9","structure":{"claims":41,"claims_by_group":{"comparisons":2,"experience":2,"questions":6,"restated":18,"views":13},"limitations":2,"links":{"context":3,"support":48},"ma_question":true,"named_voices":10,"passages":35,"sources":16,"sources_by_kind":{"commentary":8,"media":8}},"title":"No systemic chemotherapy: why most speakers stress ongoing treatment and monitoring","title_holders":{"cited_claim_ids":["claim-5766521775e3c34da416","claim-96352e67045df956ae9a","claim-6f53cbb0427835294c34","claim-55310046dca12bd3e5ac","claim-a84d2dcf76f534464dc9","claim-de335989b38362167c48","claim-c584e42d4a330eb376c4","claim-db6a8d5e007e0d793382","claim-17ac3f8fcd9d4bcf4fe8","claim-02d1e84029dfd4d81239","claim-2b016c1b412ce16fe805","claim-8e87be1400cd31942bd8","claim-ec3a9df132aacf279200","claim-780e187e5998bdbb4c32","claim-aeef47ed424b97081e5a","claim-66cb74949bfd3fb1582c","claim-16495f476bed881b0686","claim-cb7548df9104eb00d0a7","claim-2ede9fda244295005c29","claim-c7bffd344ed57c3a2009","claim-d1e158424608a310568b","claim-6f7c67df55ce07d99190","claim-86f075bf30fa56088d9a","claim-b2f84e877a947ac656a6","claim-7da459efa1a84bf24296","claim-d106f90a5f8169ea596f"],"clinicians":false,"holders":9,"speakers":10,"view":"reading"},"evidence_line":"41 statements from 10 speakers in 16 sources, 8 of them podcasts or videos","holder_line":"9 of the 10 named speakers in this finding hold this view"},{"cited_clinicians":0,"id":"F10","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":7},"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":2,"passages":7,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Quality of life: a speaker notes early experimental-arm gains but awaits comparison","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b83839f6b6f9404cedb4","claim-07af057035d4e1bdbc3d"],"clause":"await comparison","holders":1},"cited_claim_ids":["claim-9cbb64e7b82c8e8df574","claim-b2db61ba5d64cb14509f","claim-8f8eaf1575170a4131e1"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"11 statements from 2 speakers in 5 sources, 3 of them podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “await comparison”"},{"cited_clinicians":1,"id":"F11","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Inotuzumab next? What a speaker asks; one keeps frontline CAR-T in trials","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-06396f1d8dbf47b0f400","claim-7604efec214210fd2c7a"],"clause":"one keeps frontline CAR-T in trials","holders":1},"cited_claim_ids":["claim-bfdd3eaede8428b5b1f5"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"5 statements from 3 speakers in 4 sources","holder_line":"1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “one keeps frontline CAR-T in trials”"}],"open_question":{"basis":"From finding F1 (75 statements from 14 speakers in 26 sources)","cited_claim_ids":["claim-a0d72cb8d1ff398fb7b2","claim-0d602c692c93c8fa7b13","claim-05328a5ed57bf5604816","claim-9e05de20b1b7f386f25d","claim-9badfe0fba044008f6de","claim-ad1cd81be748ee40ecf9","claim-0c765975884a2e10961d","claim-8c2da1002b7ef475e079","claim-c1efc6df822cf382e8ac","claim-fa8c5bf56a6152552604","claim-f5f01c26ae0c7c9ff8a6","claim-3a44e07803fe2ff1ee7f","claim-1dffd5ea603514c37115","claim-d2ffbc0729608cd15420","claim-5e5080e62045ab33dbfe","claim-416bef78c3d354996cc8","claim-830449eac80168800a58","claim-5e81fa3ef01db3533fe1","claim-3760ee383ff0417e845a","claim-04990bf9ac304b9bd87c","claim-17494cf44294c801f7ee","claim-6ca43860f0a38cf20d3f","claim-acaede6123ae46cd08c7","claim-c66bb78300a9f44084aa","claim-4d3125b0fcf5761dc566","claim-5339ac9e59a0b24f424a","claim-4c541526545b5bcd356e","claim-f57ed09ad995d0a722e9","claim-d7a54c709c091aef56ac","claim-5522b5770cbd443c7fe1","claim-8809d0b2114727c4c006","claim-eb9645517986d76062f8","claim-84b24729d43c9ca648e8","claim-6a11f464861eed56a46f","claim-b5c08ac5fe622a36f735","claim-03202870190d6ab7c361","claim-b1957a035f7b92787b67","claim-5f3184bcc95641b600ac","claim-ba9d24efeb82435267bc","claim-5ae5ff69c3c648211b55","claim-5cffa5e3e0b7eb0b9bd2","claim-f5d593a5f03a77d31cce","claim-ca1f4653e440d9f345e3","claim-a3a6ec075fe5058d93b8","claim-58b5afc2378a2a7d073e","claim-46e64fb512766bdb6051","claim-09fdd8dc07eaff3c6105","claim-d22d96fe2f33b79646b8","claim-a6a5e911640a9f6fddd1","claim-89f05282d497199077c2","claim-e1b20ede21b83e744bf7","claim-ec61296a95e967e1b296","claim-3c0b77ad8864b5d2de50","claim-4f76905d6dbbbfa5a7d8","claim-4aca033d4cc359f2f4b5","claim-ffae41e2efe70f4e02f9","claim-5cad49f5fa040a606fd9","claim-f5d593a5f03a77d31cce-3fb5a06c","claim-e37fecbe83f1bae5ac4a"],"finding_ids":["F1"],"question":"What evidence on MRD depth and durability, IKZF1-plus or other high-risk biology, and longer-term relapse control do clinicians say they need before omitting first-remission allogeneic transplantation after ponatinib–blinatumomab in fit, MRD-negative adults with newly diagnosed Ph+ ALL?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers disagree over transplant omission, especially for fit adults with negative MRD or high-risk biology"},{"id":"section-2","level":2,"title":"Speakers make ponatinib use conditional on vascular risk and weigh dasatinib as an alternative"},{"id":"section-3","level":2,"title":"Speakers endorse chemotherapy-sparing frontline therapy, while differing on whether the evidence changes or confirms practice"},{"id":"section-4","level":2,"title":"Speakers distinguish disease-control benefit from a settled OS conclusion"},{"id":"section-5","level":2,"title":"Speakers value randomization but question comparator relevance and what the comparison can establish"},{"id":"section-6","level":2,"title":"Speakers ask what MRD negativity means before using it to select or omit transplantation"},{"id":"section-7","level":2,"title":"Speakers make CNS protection a condition of chemotherapy sparing"},{"id":"section-8","level":2,"title":"Contributors see access and cost as limits on adoption and debate whether downstream savings offset drug expense"},{"id":"section-9","level":2,"title":"Speakers describe ongoing treatment and support needs behind chemotherapy avoidance"},{"id":"section-10","level":2,"title":"One interviewee reports early quality-of-life improvement but limits the evidence to the experimental cohort"},{"id":"section-11","level":2,"title":"Whether InO could improve outcomes further, and where investigational or salvage CAR-T might fit"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":15}],"id":"T1","label":"Primary endpoint: Number of patients who are event-free"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":4}],"id":"T2","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":11},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":33},{"id":"F9","shared_claims":3}],"id":"T3","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":42},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":2},{"id":"F9","shared_claims":2}],"id":"T4","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":17},{"id":"F5","shared_claims":23},{"id":"F8","shared_claims":1}],"id":"T5","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T18:36:39.581269Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T18:55:11Z","record_hash":"6cf76c9e9ffe25ce7eec2020856191e656a8f0cbae2d7d8a02826edaa0603c3f","release_hash":"17954ab7b4a4b42ac910538040e137c0c85f90ada4b2274dc2ff29f0f0d62f4b","report_id":"erudio-nct04722848","run_id":"99848027-f99c-4e9f-961c-55780f5ce4b0","schema_version":"5.0","slug":"gimema-all2820-nct04722848","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited read GIMEMA ALL2820 as supporting less systemic chemotherapy because of better disease control, but speakers differ on how far negative MRD justifies withholding HCT, particularly with adverse biology. In discussion of first-line treatment choice, a physician favors ponatinib-based treatment when vascular risk permits, whereas a hematologist–oncologist prefers dasatinib–blinatumomab, citing preclinical T-cell findings. Longer follow-up is needed to assess durability and late toxicity; overall-survival superiority remains unproven.","examples":[{"claim_id":"claim-4230571855e8cd32bb87","finding_id":"F3","identity_check":"npi_registry","month":"2026-01","region":"US","role":"Physician","source_type":"x_video","statement":"considers GIMEMA ALL2820 perhaps the most provocative and important study seen at ASH that year, within efforts to reduce frontline chemotherapy in adult ALL."}],"meta_description":"108 sources screened · 480 verified statements (85 from clinicians verified by NPI or staff page) from 69 sources · 11 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T18:55:11Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":108},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on review-based comparisons of chemotherapy-free and chemotherapy-based frontline treatment for Philadelphia-positive acute lymphoblastic leukemia; a view on comparative survival evidence supporting chemotherapy-free blinatumomab plus a TKI in newly diagnosed adult Ph-positive ALL.","2 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","81 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 16 sources about other trials or topics are not included.","This report describes the sources reviewed for this edition, not a representative sample of HCP opinion. Repeated posts, relayed presentations and multiple interviews must not be counted as independent clinicians or independent confirmation.","Two passages in one Bluesky thread were not fully assessed for clinician views, so additional relevant opinions may be absent.","Two review-based survival summaries were not used because the accounts of their original attribution were incomplete. They cannot support additional named interpretations here.","Some spoken passages cannot be assigned to a named participant. They may belong to a participant named elsewhere in that source and must not be counted as additional people or used to establish disagreement between identifiable individuals.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Professional descriptions for nine speakers are descriptions in their sources rather than independently confirmed credentials. Descriptions of trial participation or authorship likewise come from those sources and do not make those views independent assessments.","Interim experimental-arm reports, historical comparisons, meeting presentations and publication-based accounts use different estimates, denominators and follow-up descriptions. They are not pooled or treated as evidence that an individual changed their mind. Some accounts also contain numerical inconsistencies or unclear drug, mutation and dosing terminology.","No standalone protocol was obtained from the ClinicalTrials.gov entry for this edition. Speakers' questions about the registered five-month assessment, the publication's 24-month EFS estimate and differing endpoint definitions remain unresolved here; they do not establish a protocol violation.","Exact regulatory labels for either trial regimen were not available for independent checking. Authorization, reimbursement, filing expectations and cost statements remain specific to the source's geography and timing, not a current international regulatory or economic assessment.","External studies are included only where speakers use them to weigh the frontline adult Ph+ ALL decision. Their outcomes, treatment schedules and risk thresholds are not ALL2820 results. Pediatric assertions and disconnected discussions of other settings are outside this synthesis."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":5,"linkedin_post":6,"other":0,"podcast":3,"publication":1,"registry":0,"regulatory":0,"x_thread":36,"x_video":1,"youtube":17},"by_evidence_role":{"commentary":68,"results":1},"count":69,"evidence_window":{"end":"2026-11-16","start":"2024-02-22"},"retrieval_snapshot":"2026-11-19T14:22:17.616458Z","timeline":[{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W17"},{"count":6,"week":"2024-W50"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W05"},{"count":2,"week":"2025-W09"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W48"},{"count":3,"week":"2025-W49"},{"count":3,"week":"2025-W50"},{"count":2,"week":"2025-W51"},{"count":2,"week":"2025-W52"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":19,"week":"2026-W42"},{"count":10,"week":"2026-W43"},{"count":1,"week":"2026-W44"},{"count":2,"week":"2026-W45"},{"count":3,"week":"2026-W46"},{"count":1,"week":"2026-W47"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04722848:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04722848:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42874102","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ysesz2mn5ig5vitaq3qdjos-3m7gsjcp5b32a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b7nwp7dlrtxfcch6scegoqjl-3m7fugf6ads24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-f5a7rg43t2cwqdmxw6e4tnkm-3lhxznip6m227","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-f6z3tzq33ypiqbmdinhqynlm-3m7gyxfytxn22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3lq5qdb222c2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3mxuical5tc2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3mxw4koosnj26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3mxzb55jegh2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3myaijft3t52z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ogu7udgs2khcvgdkx6cqbalk-3lcvta2mwgk2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ogu7udgs2khcvgdkx6cqbalk-3lcvvm4iyhs2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ogu7udgs2khcvgdkx6cqbalk-3m7fqojomck2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tekhmoswn2dxysqe7c73fzlt-3mxyvru436c2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tekhmoswn2dxysqe7c73fzlt-3myiei3nqys2g","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7516346645111050240","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7516436446933594112","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7516617910195433474","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7516935063125757952","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7517735318205222912","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519121904411131904","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5f64f9","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:991546","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bef369","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1766222151558783044:dd760146-c855-4791-b12d-616b0f76d2e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866253950992998454:8d52e672-4c4a-4c6e-b7dd-e95cdd8eb2a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866257068505866352:9c8bb497-0ef5-45e0-b50b-76412df64838","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866259461272490436:c019d391-ac1c-4c6c-9b93-14c3cf2f85a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866263055354761264:855028a7-1287-4204-ae29-d112ee70aa87","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866267477757620440:4132355d-b166-4c89-8e7b-29efc96a14f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1868346659790332389:412921fc-6a8b-4444-b82d-d1cc8189cd06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1868412596703166628:f8a0803c-4d72-442e-ba4c-cf65778911e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882177282049282049:38d91b92-8b16-42d0-b99d-56b3e52f6778","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884164639715430597:d246a864-2834-43a1-a222-2e8df00c440a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894351078495326555:7436a842-945d-4b25-a16c-fcfce07f21dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894351655866699876:df4a274b-5874-425c-8f90-585e535e159a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927347345693216811:6fbe8e4f-50d7-4a54-9d3c-b7983cb634da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934187653596893458:1737c736-746e-4f1a-b8bb-a6cea4167c3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1994136135140774399:06cb625d-a6e1-482e-beff-26f2ff16d9ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1995883992768544801:e0fa0512-ec81-4628-a236-ab56df546508","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1996653522927210531:fa801763-3429-4d10-83b6-0bb6dcd51f4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997678637424820442:c0b15b65-d2cb-42ed-88d2-74ae21597cc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997701579042930994:51d0df88-215b-436b-bba6-a0490c2ce83d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997764206532186506:32788bd0-eddf-4217-8bcf-d3c4e288ef6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998331320502477310:f8dff40b-fd73-492f-8c1e-6fddee4fa672","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1999004186374225993:2e639998-8dfc-4a1f-af13-371399d7845f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2002755936784466363:64ef61c2-59c6-4f0c-b127-e80cd88cd327","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2003526275059654856:33f11904-7ed9-41c8-a68e-0b130cb6b716","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2005358356505198738:89e89af1-cc63-4f5f-8676-eec3257f4a23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2006700782629040311:3adf7afc-e3d8-4cee-aa3a-3c01f8cde282","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013239112178811085:e1d8d374-f595-4d24-b0f3-770678896a93","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013239230512673084:aaa89730-2a52-43f9-b7b8-ef84577c800c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051415462303457727:389b79af-3902-4264-9bc5-daf45818d351","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065119117053501465:ce1bf1e1-969c-48c8-a48c-41c4a7d49ff6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073216731380670557:e896a354-369e-4952-972e-28434dc3600e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2083225335030513769:cd5e9580-06f7-4918-ad26-261fd391f8b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093673712918605914:b053cea4-7768-403f-ae53-db706bcfa210","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097719024440205641:87bb3010-43fc-4a69-85de-4f6a98bc43c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103962759679586730:478edf2f-c5d7-4602-bcc3-86485d20b70b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110480776630346156:3d2aa39e-8332-46de-b05c-4feee70e7d3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110512356023472309:1091c4ec-22f1-4668-a50a-59603a5005d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110525167738794080:f9bf51c1-b120-4e86-8050-b7335f109552","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110670670564581419:ef575234-0166-4538-880d-1d15d1917edf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110704189043032183:de8c99a1-2fff-4398-bb6d-7ba51ec999ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110730676605755658:fb704880-fabf-4265-8427-1290ffbd8512","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110732516134908229:cfe3a0b7-783f-4478-9d97-b44d48afff8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110735916444881383:eb44d7dc-85e3-4711-8373-c587dd6e6f48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110930316776902951:0f90b7ac-f1cc-48e2-835a-cdb04cb715b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111169533868396847:8ebd92fb-4a4a-4b75-b685-f92000ee6dfa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111170366596948446:a9f34810-b15c-4901-a9f7-479ed81425ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111547826685596034:15860e63-3ade-4312-8db8-68346098d354","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111576630074470800:a44308f2-9905-4584-a660-fd5c3248fc8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111662820144422996:2086cae5-7a9c-435f-9584-27e3c87e1bde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111675179147608408:3d4f737e-6e20-4250-a32c-f388dad50746","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111968581726466308:856479fb-5a47-4dc6-a01d-2b2ef72c62d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112212389806453237:7f6c8b0f-54e6-41ca-b12c-3fcee2c0311e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112258986779250768:c295fafe-a9ab-4baf-bef4-dd0680a63e60","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112285218711462142:57e28b5a-f25b-40d2-a8fe-44ab80715dd5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112288200848802185:e1dab42f-1c06-4a7e-b48c-0f65a9fd85be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112586661796389268:d38355ff-3b17-45e3-8e3a-70ed068ae074","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112922849904136541:5e16bd86-c52a-4538-b906-9cb4e011dce8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113698295864549482:90120b50-3efa-4a68-a436-47cc0023c01a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113784621108252984:8d1bad76-dffd-404f-b8fa-af6bdd8df530","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114747888647758125:0e71614c-2ee1-41c4-81a9-4d716dd87d5d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115553727721718083:59a65dc9-304b-499f-a1d5-a6888602c242","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120015552429113562:a6722d74-77b9-4e33-879b-52b39fafbe01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120533255489556647:a40d09ad-e697-4f59-9dc0-bef1d8e6181f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120592590340800832:c3d6deac-8b0e-4a83-98d3-c84b53209384","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121277437208080444:a73075d3-7145-47fd-9c05-ccf7c8e4af02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122378784892743770:fa8cd814-2621-4edc-8acd-56516edffab1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122379454919897287:afcc6130-f407-427f-b518-43bd5295f17f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2015847209531801996","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2K9GTfKt2jc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BNUpCFoo-MM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DmuFhe8xWoc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:EXIZtK_5ZHw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:MKtw4C4uoio","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:RBSIneQRePA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Uayn2sbQ7Q4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_DGLXYujtyw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bICmVCf_47k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:eAz4BD8pzBs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:eyhL1-_9h0s","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lUaTiXn7UL0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sEqRFZK01AQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uB0BA80C884","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:v2NFK1aZ5bU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xUQC7gASKi8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yvGH-3pW4Wg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":14,"linkedin_post":6,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":67,"x_video":1,"youtube":17},"by_evidence_role":{"commentary":108},"count":108,"evidence_window":{"end":"2026-11-16","start":"2024-02-22"},"retrieval_snapshot":"2026-11-19T14:22:17.616458Z","timeline":[{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W17"},{"count":10,"week":"2024-W50"},{"count":2,"week":"2025-W04"},{"count":2,"week":"2025-W05"},{"count":1,"week":"2025-W07"},{"count":2,"week":"2025-W09"},{"count":2,"week":"2025-W22"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W48"},{"count":7,"week":"2025-W49"},{"count":6,"week":"2025-W50"},{"count":4,"week":"2025-W51"},{"count":2,"week":"2025-W52"},{"count":1,"week":"2026-W01"},{"count":2,"week":"2026-W04"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":27,"week":"2026-W42"},{"count":13,"week":"2026-W43"},{"count":2,"week":"2026-W44"},{"count":2,"week":"2026-W45"},{"count":6,"week":"2026-W46"},{"count":3,"week":"2026-W47"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":10,"linkedin_post":33,"other":0,"podcast":96,"publication":3,"registry":0,"regulatory":0,"x_thread":112,"x_video":3,"youtube":223}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Iclusig"],"label":"ponatinib","slug":"ponatinib"},{"brand_names":["Blincyto"],"label":"blinatumomab","slug":"blinatumomab"},{"brand_names":["Gleevec","Imkeldi"],"label":"imatinib","slug":"imatinib"}],"indications":[{"reason":"Unmapped registry condition: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)","status":"unmapped"},{"reason":"Unmapped registry condition: ALL, Adult","status":"unmapped"},{"reason":"Unmapped registry condition: Philadelphia-Positive ALL","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Leukemia","slug":"leukemia"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"GIMEMA ALL2820","aliases":["GIMEMA ALL2820","ALL2820","Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib"],"brief_title":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)","ALL, Adult","Philadelphia-Positive ALL"],"display_condition":"newly diagnosed adult Ph+ ALL","display_interventions":[["ponatinib","blinatumomab"]],"enrollment":{"count":236,"type":"ACTUAL"},"interventions":[{"name":"Ponatinib + Blinatumomab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Chemotherapy + Imatinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04722848","official_title":"Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_endpoints":[{"description":"event-free survival rate","measure":"Number of patients who are event-free","timeFrame":"at 5 months"}],"registered_date":{"date":"2021-01-25","type":"ACTUAL"},"registry_last_updated":"2025-01-23","registry_url":"https://clinicaltrials.gov/study/NCT04722848","short_name":"GIMEMA ALL2820","short_name_basis":"canonical_name","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","start_date":{"date":"2021-09-08","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"ALL2820","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}